Skip to main content
Premium Trial:

Request an Annual Quote

Mayo Clinic Research Team Models SARS Enzyme; Identifies Potential SARS Drug Targets


NEW YORK, Aug. 20 (GenomeWeb News) - After simulating the three-dimensional structure of a SARS enzyme responsible for the replication of the deadly virus, a Mayo Clinic research team has identified via computer twenty molecules that could potentially interact with the enzyme to thwart its function.

 

The 3-D structure of the functionally important SARS enzyme was published last week in the online version of the journal Proteins: Structure, Function and Bioinformatics, after Yuan-Ping Pang and his research group solved the structure using x-ray crystallography techniques and computer modeling.  

 

Pang used a Mayo Clinic in-house chemical database to search for molecules that could potentially interact with the SARS enzyme. The computer structures of the 20 chemicals he identified were sent to the Southern Research Institute in Birmingham, Ala.for further testing to see if they could work as anti-SARS drugs.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.